IL17A and Langerhans cell histiocytosis: In the present preclinical in vitro study conducted with human primary Mo-DCs from LCH patients, we finally investigated the potential benefit of adding neutralizing anti-IL-17A antibodies to low doses of LCH-directed chemotherapeutic agents, in the attempt to mimic future therapies.